<DOC>
	<DOCNO>NCT00281983</DOCNO>
	<brief_summary>RATIONALE : Giving chemotherapy donor bone marrow transplant help stop growth cancer cell . It also help stop patient 's immune system reject donor 's stem cell . Also , monoclonal antibody , alemtuzumab , find cancer cell either kill deliver cancer-killing substance without harm normal cell . When healthy stem cell donor infused patient may help patient 's bone marrow make stem cell , red blood cell , white blood cell , platelet . Sometimes transplanted cell donor make immune response body 's normal cell . Giving methotrexate , cyclosporine mycophenolate mofetil transplant may stop happen . Once donated stem cell begin work , patient 's immune system may see remain cancer cell belong patient 's body destroy ( call graft-versus-tumor effect ) . Giving infusion donor 's white blood cell ( donor lymphocyte infusion ) may boost effect . PURPOSE : This phase I/II trial study side effect give fludarabine together cyclophosphamide see well work treat patient undergo donor stem cell transplant B-cell chronic lymphocytic leukemia Waldenström 's macroglobulinemia .</brief_summary>
	<brief_title>Fludarabine Cyclophosphamide Treating Patients Who Are Undergoing Donor Stem Cell Transplant Chronic Lymphocytic Leukemia Waldenstrom 's Macroglobulinemia</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine feasibility safety induction therapy comprise fludarabine cyclophosphamide follow allogeneic stem cell transplantation patient high-risk B-cell chronic lymphocytic leukemia lymphoplasmocytic lymphoma ( Waldenstrom 's macroglobulinemia ) . Secondary - Determine incidence kinetics clinical molecular remission patient treat regimen . - Determine event-free overall survival patient treat regimen . - Determine duration clinical molecular remission relation underlie cytogenetic deviation patient treat regimen . - Determine kinetics extent lympho-hematopoietic donor chimerism patient treat regimen . OUTLINE : This multicenter , open-label , nonrandomized , pilot study . - Cytoreductive therapy : Patients receive 3 course cytoreductive therapy comprise fludarabine IV cyclophosphamide IV day 1-3 ( without rituximab IV day 1 ) . Patients refractory fludarabine-containing therapy may receive alemtuzumab IV 12 week OR cytotoxic salvage regimen cytoreduction . - Conditioning regimen : Patients receive 1 follow condition regimens* : NOTE : *Patients achieve partial response cytoreductive therapy receive regimen 3 . - Regimen 1 : Patients receive fludarabine IV cyclophosphamide IV day -7 -3 . If stem cell collect unrelated donor , patient also receive anti-thymocyte globulin ( ATG ) IV day -4 -1 . - Regimen 2 : Patients undergo total-body irradiation day -9 . Patients receive alemtuzumab IV day -8 -4 fludarabine IV cyclophosphamide IV day -6 -2 . - Regimen 3 : Patients receive fludarabine IV day -7 -3 , busulfan IV orally day -7 -5 , cyclophosphamide IV day -3 -2 . If stem cell collect unrelated donor , patient also receive ATG day -3 -1 . - Allogeneic peripheral blood stem cell transplantation ( PBSCT ) : Patients undergo allogeneic PBSCT day 0 . Patients receive filgrastim ( G-CSF ) subcutaneously daily start day 5 continue blood count recover . - Graft-versus-host-disease ( GVHD ) prophylaxis : Patients receive cyclosporine IV begin day -1 continue approximately day 100 . Patients treat condition regimen 1 3 also receive methotrexate IV day 1 , 3 , 6 OR oral mycophenolate mofetil twice daily day 0-50 . Patients evidence residual disease least 4 week completion cyclosporine undergo donor lymphocyte infusion ( DLI ) . - DLI : The donor T-lymphocytes collect PBSCT donor without prior G-CSF mobilization . Patients receive DLI every 8 week presence residual disease absence GVHD . After completion study treatment , patient follow periodically . PROJECTED ACCRUAL : A total 70 patient accrue study .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Lymphocytic , Chronic , B-Cell</mesh_term>
	<mesh_term>Waldenstrom Macroglobulinemia</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Fludarabine phosphate</mesh_term>
	<mesh_term>Antilymphocyte Serum</mesh_term>
	<mesh_term>Mycophenolate mofetil</mesh_term>
	<mesh_term>Busulfan</mesh_term>
	<mesh_term>Cyclosporins</mesh_term>
	<mesh_term>Cyclosporine</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<mesh_term>Alemtuzumab</mesh_term>
	<mesh_term>Mycophenolic Acid</mesh_term>
	<mesh_term>Vidarabine</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Diagnosis Bcell chronic lymphocytic leukemia lymphoplasmocytic lymphoma ( Waldenstrom 's macroglobulinemia ) Must poor prognostic feature low probability successful autografting , define one follow criterion : Progressive disease unfavorable cytogenetics ( deletion mutation critical region chromosomes 11q and/or 17p [ p53 ] ; and/or unmutated status immunoglobulin V_H gene region ; and/or usage V_H 321 gene ) , define 1 following : Doubling lymphocyte count nodal involvement within 3 month less Progressive decline platelet count and/or hemoglobin value define Binet stage C disease ( 50 % less baseline value within 3 month ) due immune mechanism Symptomatic splenomegaly Discomfort imminent complication due large tumor mass B symptom Refractory disease early relapse ( within 12 month ) treatment fludarabinecontaining regimen Relapsed autologous stem cell transplant ( SCT ) Insufficient stem cell harvest intend autologous SCT Presence clonal CDR III rearrangement detect polymerase chain reaction No Richter 's syndrome HLAidentical sibling unrelated donor available PATIENT CHARACTERISTICS : ECOG performance status ≤ 1 Creatinine clearance &gt; 60 mL/min SGOT , SGPT , bilirubin &lt; 2 time normal Normal cardiac function determine ECG echocardiographic examination Inspiratory vital capacity , FEV_1 , DLCO &gt; 50 % predict No serious localize systemic infection No concurrent malignant disease No impair organ function No uncontrolled diabetes No uncontrolled hypertension Not pregnant nursing Fertile patient must use effective contraception No HIV infection No hepatitis B C infection No concurrent alcohol drug abuse No dementia alter mental status would preclude give informed consent PRIOR CONCURRENT THERAPY : Not specify</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>April 2007</verification_date>
	<keyword>B-cell chronic lymphocytic leukemia</keyword>
	<keyword>refractory chronic lymphocytic leukemia</keyword>
	<keyword>stage III chronic lymphocytic leukemia</keyword>
	<keyword>stage IV chronic lymphocytic leukemia</keyword>
	<keyword>Waldenström macroglobulinemia</keyword>
</DOC>